JPRN-jRCT2031200214进行中（未招募）1 期
An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects
Clinical, Medicine Creation Japan and Asia Clinical Development Department0 个研究点目标入组 42 人开始时间: 2020年11月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 55age old（—）
- 性别
- All
入选标准
- •Participants who meet all of the following criteria will be eligible for participation in the study
- •1. Body mass index (BMI) between 18.5 to 25.0 kilogram per square meter (kg/m^2), inclusive, at screening
排除标准
- •Participants who meet any of the following criteria will be excluded from this study:
- •1. Following ocular disorders
- •a. Current evidence of Grade 2 or higher corneal disorder
- •b. Current evidence of active macular disorder (example, age-related macular degeneration, central serous chorioretinal disease)
- •2. Any clinically abnormal symptom or organ impairment found by medical history at screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at screening
- •3. A prolonged QT/QTc interval (QT interval with Fridericia's correction [QTcF] greater than [>] 480 millisecond [ms]) demonstrated on ECG at screening or baseline
- •4. Known history of food allergies or presently experiencing significant seasonal or perennial allergy at screening
- •5. Known history of allergies or reactions to rabeprazole or rifampin or known anaphylactic reaction to any drugs at screening
研究者
相似试验
已完成
不适用
An open-label, single-dose study to evaluate the excretion and metabolism of oral [14C]-ONO-5788, and absolute bioavailability of oral ONO-5788 in healthy adult male subjectsacromegalyNL-OMON48245Ono Pharma UK Ltd.12
进行中（未招募）
1 期
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Aticaprant (JNJ-67953964)CTIS2023-503258-11-00Janssen - Cilag International48
进行中（未招募）
1 期
A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated CirrhosisHCVMedDRA version: 20.0 Level: LLT Classification code 10019752 Term: Hepatitis C virus (HCV) System Organ Class: 100000004848EUCTR2016-004967-38-HUAbbVie Deutschland GmbH & Co. KG275
进行中（未招募）
1 期
A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated CirrhosisHCVMedDRA version: 20.0Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 100000004848EUCTR2016-004967-38-IEAbbVie Deutschland GmbH & Co. KG343
进行中（未招募）
1 期
A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated CirrhosisHCVMedDRA version: 20.0Level: LLTClassification code 10019752Term: Hepatitis C virus (HCV)System Organ Class: 100000004848EUCTR2016-004967-38-GRAbbVie Deutschland GmbH & Co. KG343